Platelet-Rich Plasma Guided Injections: Clinical Application in Peripheral Neuropathies by Michael-Alexander Malahias et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 13 October 2014
doi: 10.3389/fsurg.2014.00041
Platelet-rich plasma guided injections: clinical application
in peripheral neuropathies
Michael-Alexander Malahias, Dimitrios Chytas, George C. Babis andVasileios S. Nikolaou*
2nd Orthopaedic Department, Athens University, Athens, Greece
Edited by:
Hannes A. Rüdiger, Schulthess Clinic,
Switzerland
Reviewed by:
Christopher Lu, Georgetown Hospital,
Canada
Rema A. Oliver, University of
New SouthWales, Australia
*Correspondence:
Vasileios S. Nikolaou, 2nd
Orthopaedic Department, Athens
University, 21 DimitriouRalliStr,
Maroussi, Athens P.C 15124, Greece
e-mail: vassilios.nikolaou@gmail.com
Platelet-rich plasma (PRP) is defined as an autologous concentrated preparation of platelets
and their associated growth factors in a small volume of plasma. The presence of these
growth factors has stimulated the scientific community to search about possible bene-
fits of the use of PRP in tissue regeneration. Provided that previously in vitro and animal
research demonstrated that PRP could probably play an important role in the treatment
of neural tissue disorders, we aimed to review the current literature, regarding the clinical
studies that have been conducted to confirm this hypothesis. More specifically, we have
reviewed the literature concerning the clinical application of PRP in peripheral neuropathies
and investigated if there is strong evidence to establish the use of PRP in clinical practice
as a therapeutic option. In contrast with animal studies, we have been able to identify
only few clinical data concerning the use of PRP in peripheral neuropathies. We found five
trials matched to our research that yields positive and promising results for the future for
the application of PRP for the therapy of disorders of the peripheral nervous system. It is
obvious that this interesting field of research gives to the scientists the ability to expand it
extensively, in terms of both quality and quantity.
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INTRODUCTION
Platelet-rich plasma (PRP) is an innovative and promising
approach in tissue regeneration. PRP is defined as an autolo-
gous concentrated preparation of platelets and their associated
growth factors in a small volume of plasma (1). Platelets are a
natural source of a myriad of growth factors in their natural and
biologically determined ratios (2).
The application of PRP has been documented in many
fields. Musculoskeletal practitioners began using PRP for chronic
tendinopathy in the early 1990s. The growth of PRP ther-
apy has relied primarily on anecdotal or case studies. Histor-
ically, there have been few controlled trials to prove the effi-
cacy of PRP. Recently, however, there has been an emerging
literature on the beneficial effects of PRP for tendon, ligament
or muscle injuries, maxillofacial therapies, dentistry, cosmetics,
wound healing, cardiothoracic surgery, ear–nose–throat surgery,
neurosurgery, urology, and ophthalmology.
Among all these data, a relatively new question upon basic sci-
ence’s researchers is the effect of PRP on neural tissue. There is an
important number of animal studies that argue in favor of the use
of PRP in neuropathies. Most recently, Giannessi et al. (3) experi-
mented with an autologously generated PRP suturable membrane
in sciatic nerve neurotmesis–neurorrhaphy (rat model). He con-
cluded that PRP may enhance peripheral nerve regeneration. Far-
rag et al. (4) showed in a rat model that there is an improved
functional outcome with the use of PRP – in comparison with no
bioactive agents [platelet-poor plasma (PPP)] – on facial nerve
regeneration. In another study, Park and Kwon (5) proved that
PRP limits the nerve injury caused by 10% dextrose in the rabbit
median nerve (carpal tunnel model). On the other side, Piskin
(6) suggested that platelet gel does not improve peripheral nerve
regeneration, but Kaplan (7), from the same team, 2 years later,
observed that platelet gel has a positive effect on sciatic nerve
repair (animal studies). In different fields, Elgazzar (8), Sariguney
(9), and Shen (10) concluded that PRP can be a novel treatment
for peripheral or central nervous system diseases.
BUT HOW COULD PRP POSSIBLY REACT TO NERVE TISSUE?
Platelets include alpha granules, which contain mitogenic and
chemotactic growth factors such as IGF-1, bFGF, and TGF-beta
(11). Although they are not classical neurotrophic factors, the
effects of these growth factors on nerve regeneration have been
comprehensively studied.
About nerve entrapment syndromes, Mulvaney (12) intro-
duced a new theory about non-surgical treatment. He showed
that peripheral nerve entrapments can be treated with real time
ultrasound-guided hydro-neurolysis. Hydrodissection around the
entrapped nerve could possibly work to loosen the scar tissue
allowing more nerve impulses to pass through. Independent of
the fluid (PRP or local anesthetic or corticosteroid or normal
saline 0.9%), hydrodissection works in a mechanical and non-
biochemical way, but it maybe improves cases of ischemic damage
to a nerve due to scar tissue banding.
Giannessi (3) believes that the use of PRP could perform an
action, not only as a source of bioactive proteins, but also as
a nerve guide to hold the scar reaction and thus induce axonal
regeneration.
Provided that the previously mentioned in vitro and animal
research demonstrated that PRP could probably play an impor-
tant role in the treatment of neural tissue disorders, we aimed
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to review the current literature, regarding the clinical studies that
have been conducted to confirm this hypothesis. More specifically,
we have reviewed the literature concerning the clinical applica-
tion of PRP in peripheral neuropathies and investigated if there is
strong evidence to establish the use of PRP in clinical practice as a
therapeutic option.
LITERATURE REVIEW
We searched on Medline, Cochrane Database, and EMBASE using
the key words “PRP,”“clinical study,”“peripheral neuropathy,” and
“trial.” Initially, one reviewer conducted the literature search and
retrieved the references to be evaluated. A second reviewer inde-
pendently selected the trials to be included in the review and also
screened the reference list from the selected articles in order to
identify studies that have been missed at the initial search.
In contrast to animal studies, we have been able to identify
only few clinical data concerning the use of PRP in peripheral
neuropathies. We found five trials matched to our research.
According to Anjayani et al. (13), PRP injection could promote
improvement of peripheral neuropathy in patients with Hansen’s
disease. This double-blind, randomized, clinical trial included 60
patients with neuritis leprosy (Hansen’s disease). This kind of
nerve damage, caused by Mycobacterium leprae, is characterized
by granulomatous inflammation of the epineuron of peripheral
nerves. The sensory loss appears to be earlier and more frequent
among patients. In this research,patients were divided randomly in
two comparable groups and treated either with a PRP perineural
injection or a PPP injection as control. Perineural injection of
PRP proved to be significantly more effective in visual analog scale
(VAS) and two-point discrimination test. This result is in favor
of the positive effect of PRP in nerve regeneration. However, the
conclusions of this high-quality study need to be confirmed with
further research in the future, with longer observation times, while,
on the other hand, the optimal frequency of PRP injections should
be determined (13).
Sanchez et al. (14) described a case report of a healthy young
man who suffered peroneal nerve palsy with drop foot after mul-
tiple ligament injuries of the knee. In this case, the patient had
already undergone a conservative treatment for 11 months with-
out any improvement. Then, with the use of ultrasound guidance,
he was treated with intraneural injections of plasma, rich in growth
factors. At the follow-up period of 21 months, he was assessed by
electromyography (EMG), ultrasound echogenicity, and manual
muscle testing. At the end of this period, the patient expressed
partial recovery, so that he was satisfied with running without
orthosis. EMG study showed complete reinnervation for the per-
oneallongus and a better reinnervation for anterior tibialis muscle,
compared with previous examination. Sensitivity of the peroneal
nerve distribution area was also fully recovered. This case report
introduces a novel technique of management of nerve palsy, but,
according to the authors, more extensive research is required for
the clarification of the mechanism of action of PRP. Finally, the
authors’ hypothesis that the clinical outcome might be better with
earlier application of their method, before muscle degeneration
occurs, needs to be confirmed with more studies in the future (14).
In another case study from Kuffler et al. (15), a long ulnar
nerve gap was repaired more than 3 years after the initial trauma.
This report investigated whether a collagen tube filled with autolo-
gous platelet-rich fibrin could induce sensory and motor recovery.
Two years after the operation, the patient showed good ring and
small finger motor function (could elevate 1 kg of weight). Also, he
had topographically correct two-point discrimination and ability
to feel vibration. The patient’s neuropathic pain was remark-
ably reduced and he avoided the indicated extremity amputation.
According to the authors, their technique can be improved, in
order to achieve more satisfactory results in neurological recovery
in such cases in the future (15). This study highlights the possible
benefits of PRP in neurological recovery, but has to be enhanced
with more meticulous research for more reliable conclusions.
Furthermore, Hibner et al. (16) described a surgical tech-
nique for the treatment of persistent pudendal neuralgia after
failed initial surgical decompression. A transgluteal decompres-
sion of the pudendal nerve was performed in 10 patients with
the above characteristics. After the adhesiolysis, the nerve was
coated with PRP. This retrospective clinical trial (23 months mean
follow-up) showed that eight out of nine patients reported global
improvement, with two patients reporting complete resolution of
symptoms. It was not obvious from this study the role of PRP – in
comparison to the surgical adhesiolysis and painkillers that were
injected through a pain buster catheter into the Alcock canal – in
the percentage of clinical improvement. Moreover, the small num-
ber of the patients included in the study, as well as the fact that
the trial was not prospective-randomized, emphasizes the need
for higher level of evidence papers to demonstrate the possible
usefulness of PRP in such cases (16).
Finally, Scala et al. performed a clinical randomized trial (17)
in which 20 patients who underwent a superficial parotidectomy
were separated in two groups: in the first, PRP gel was used at
the surgical site, in contrast with the second. The authors con-
cluded that the use of PRP in patients who underwent superficial
parotidectomy may play – among other positive effects – a pro-
tective role against neurological deficit of facial nerve. However,
because of the relatively small number of patients that participated
in the study, trials of higher quality are needed to support these
findings.
CONCLUSION
The variety of platelet enriched plasma’s clinical use in every
day’s practice seems to be, at least, impressive, but the evidence-
based recommendations are often equivocal. We have been able
to identify 29 clinical trials – Level I, II, or III-investigating the
possible clinical benefits of PRP in different orthopedic related
diseases or conditions. The potential clinical use of PRP in spinal
fusion, bone formation, chondropathy, osteoarthritis, lateral epi-
condylatis among other tendinopathies, muscle, ligamentous or
tendinous injuries, and skin wounds has been investigated. Surgi-
cal applications of PRP in ACL reconstruction, rotator cuff repair,
Achilles tendon tear, or non-unions show promising results in
some papers and discouraging in others. The researcher’s field
appears to be wide for PRP, but the image remains blur.
For some authors – Level I studies – PRP is suggested as a new
effective treatment in cartilage diseases, like knee osteoarthritis
(18, 19). Moreover, there are papers proposing PRP as a first-
line therapy in osteochondral lesions (20). PRP guided injections
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have proven to be efficient in chronic lateral epicondylitis (21–
23). The results in other tendinopathies, such as jumper’s knee
(24) or Achilles tendinopathy (25), are not as clear (26). In a liter-
ature review of eight controlled clinical trials was concluded that
the use of platelet concentrates into the femoral channel of ACL
reconstruction (hamstring’s tendons) probably leads to a 20–30%
higher rate of graft maturation (27). Overall, there is a tremen-
dously growing demand for clinical studies involving PRP effects
in several tissues, from bone to ligaments and tendons. But what
evidence do we have about the area of peripheral nerves?
According to the International cellular medicine society (PRP
guidelines) (28), entrapment neuropathies that have failed con-
servative treatment may be treated by percutaneous release of
nerves using PRP. This society concludes this section with the
encouragement of further investigation on this area.
We have been able to identify two randomized trials regarding
the clinical application of PRP in peripheral neuropathies. Two
other studies had a level of evidence 5, and one had a level of
evidence 4. Besides, there are several techniques of preparation
of PRP (29) and different anatomic areas of application, while
the optimal dosage, frequency of administration, and appropriate
stage of neuropathy for the use of PRP have not been investigated.
Although there are many published (in vivo or in vitro) animal
studies (and some anecdotal clinical reports) about the use of PRP
in peripheral neuropathies, literature cannot yet give a convincing
answer about the value of this therapeutic strategy. Nevertheless,
results of the so-far published clinical studies are encouraging.
Consequently, it is obvious that this interesting field of research
gives to the scientists the ability to expand it extensively, in terms
of both quality and quantity. It is obvious that more clinical trials
are needed to yield more secure evidence regarding the beneficial
effect of PRP usage in peripheral neuropathies.
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